MedTrace Logo

Evaluation of Meningococcal ACWY Immune Response in Children Aged 40 and 60 Months

NCT00601731 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 382

Last updated 2014-10-24

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate how well the immuno response against meningococcal serogroups A, C, W and Y lasts in children who were vaccinated with MenACWY as infants.

Conditions

  • Meningococcal Disease

Interventions

BIOLOGICAL

MenACWY-CRM197

Blood test, 40-months and 60-months children

BIOLOGICAL

Blood test

Blood test, 40-months and 60-months children

Sponsors & Collaborators

  • Novartis

    collaborator INDUSTRY

  • Novartis Vaccines

    lead INDUSTRY

Principal Investigators

  • Novartis Vaccines · Novartis Vaccines

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
40 Months
Max Age
63 Months
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-02-29
Primary Completion
2010-07-31
Completion
2010-09-30

Countries

  • Canada
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00601731 on ClinicalTrials.gov